MOUNTAIN VIEW, CA, Ceribell announced today the completion of a $53 million Series C financing.
Ceribell, innovator of the Rapid Response EEG, a novel non-invasive brain monitor, announced today the completion of a $53 million Series C financing, co-led by Longitude Capital and The Rise Fund. Other new investors include RA Capital Management, Redmile Group and Red Tree Venture Capital, with additional support from existing shareholders.
Ceribell is focused on making EEG widely available, more efficient, and more cost-effective to improve the diagnosis and treatment of neurological conditions with the first application for patients at risk for seizures. The Ceribell EEG System received FDA 510(k) clearance in 2017 and is commercially available in the United States.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about